Skip to main content
Equibles
BMY logo

BMY · Bristol Myers Squibb Co · Metrics

Track BMY — free

Use BMY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BMY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$62.40 -0.46 (-0.73%) At close · Sep 30
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$128.41B
Shares
2.04B
Volume · Sep 30 15.87M Avg daily vol (3M) 11.02M

BMY metrics

82 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$62.40
Market cap
$128.41B

Price action

20 metrics
Price change (1W)
+1.0%
Price change (30D)
-5.9%
Price change (3M)
+9.1%
Price change (6M)
+3.6%
Price change (YTD)
+16.5%
Price change (1Y)
+42.4%
Trailing year
Price change (5Y)
+3.7%
52-week high
$68.09
52-week low
$42.60
Change from 52-week high
-7.7%
Change from 52-week low
+47.6%
Annualized volatility
27.6%
Annualized volatility (3M)
26.4%
Beta
0.3
RSI (14D)
45.2
Price vs SMA 50
-2.5%
Price vs SMA 200
+6.1%
Avg volume (3M)
10.95M
Relative volume
1.5
Average dollar volume
$690.21M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
2.04B

Valuation

12 metrics
P / E (TTM)
13.8
Trailing earnings · reciprocal yield 7.2%
PEG ratio
0.1
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.6×
reciprocal yield 38.3%
P / book
5.8
reciprocal yield 17.4%
FCF yield
8.9%
TTM · current market cap
Buyback yield
0.0%
P / FCF
11.2
reciprocal yield 8.9%
P / operating cash flow
10.0
reciprocal yield 10.0%
Earnings yield
7.2%

Historical valuation

8 metrics
P / E historical average (3Y)
14.9×
reciprocal yield 6.7%
P / E historical average (5Y)
19.4×
reciprocal yield 5.2%
EV / revenue historical average (3Y)
3.0×
reciprocal yield 32.9%
EV / revenue historical average (5Y)
3.3×
reciprocal yield 30.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
54.9%
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-29
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
18.9%
Gross profit (TTM)
$30.75B
Operating profit (TTM)
—
Net income (TTM)
$9.28B
Trailing 12 months
Diluted EPS (TTM)
$4.55
FCF margin
23.3%
Effective tax rate
22.1%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$14.83

Growth

11 metrics
Revenue growth YoY
+5.7%
Year over year
Net income growth YoY
+153.2%
Revenue (TTM)
$49.19B
Trailing 12 months
EPS growth YoY
+153.1%
Shares change YoY
+0.5%
Year over year · more shares
Revenue CAGR (3Y)
+1.4%
Revenue CAGR (5Y)
+2.5%
EPS CAGR (3Y)
+5.5%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+2.4%
FCF CAGR (5Y)
-0.7%

Quality

14 metrics
Return on equity
41.6%
Return on assets
10.6%
Debt / equity
1.9
Current ratio
1.5
EBITDA (TTM)
—
Free cash flow (TTM)
$11.44B
Quick ratio
1.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$8.72B
Total assets
$87.63B
Total debt
$43.12B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$12.78B
Capital expenditures (TTM)
$1.34B
R&D (TTM)
$10.72B
SG&A (TTM)
$7.41B
Stock compensation (TTM)
$553.00M
R&D / revenue
21.8%
Stock compensation / revenue
1.1%

Ownership (13F)

3 metrics
13F filers
2,546
13F filer change QoQ
-18
Institutional ownership
84.3%

Short interest

3 metrics
Short interest
2.1%
Latest settlement · 5.8 days to cover
Days to cover
5.8d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$437,248
Insider-sentiment score
44 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 14272 CUSIP 110122108 13F (30d) 80 filings 31 filers Visit website Investor relations